Open AccessAnti–Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization
Author(s) -
Danny Siu-Chun Ng,
Timothy Y. Y. Lai,
Chui Ming Gemmy Cheung,
Kyoko OhnoMatsui
Publication year - 2017
Publication title -
asia-pacific journal of ophthalmology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.163
H-Index - 20
ISSN - 2162-0989
DOI - 10.22608/apo.2017308
Subject(s) - choroidal neovascularization , medicine , macular degeneration , fluorescein angiography , ophthalmology , ranibizumab , natural history , clinical trial , atrophy , bevacizumab , visual acuity , surgery , chemotherapy
Myopic choroidal neovascularization (CNV) is one of the most vision-impairing complications in patients with pathologic myopia. It is also one of the most frequently encountered non.age-related macular degeneration causes of CNV and affects young patients in the working age group. Fluorescein angiography (FA) and spectral domain optical coherence tomography (OCT) are generally indicated to confirm the diagnosis of active myopic CNV before initiation of treatment. Without treatment, natural history studies have shown that the vision outcome can be very poor. More recently, a number of retrospective, prospective and phase 3, multicenter, randomized controlled trials have established the safety and efficacy of intravitreal anti.vascular endothelial growth factor (VEGF) agents for the treatment of myopic CNV. Long-term follow-up studies have found that some of the initial vision gained after intravitreal anti-VEGF therapy may not be maintained, owing to the presence and progression of chorioretinal atrophy (CRA) adjacent to the CNV. Further research on clinical and imaging characteristics may elucidate the prognostic factors that are crucial to optimizing the treatment and prevention of visual impairment associated with myopic CNV.